Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor–Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321)

Jeff P. Sharman, Talha Munir, Sebastian Grosicki, Lindsey E. Roeker, John M. Burke, Christine I. Chen, Norbert Grzasko, George Follows, Zoltán Mátrai, Alessandro Sanna, Lugui Qiu, Ru Feng, Vu Minh Hua, Wojciech Jurczak, Matthias Ritgen, Shuhua Yi, Francesc Bosch, Catherine C. Coombs, Katherine Bao, Vishalkumar Patel, Bin Liu, Livia Compte, Ananya Guntur, Denise Y. Wang, Marisa Hill, Ching Ching Leow, Paolo Ghia, Paul M. Barr

Open source

DOI: 10.1200/jco-25-00166
Published: 2025-08
Container: Journal of Clinical Oncology
Publisher: American Society of Clinical Oncology (ASCO)
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1200/jco-25-00166,
  title = {Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor–Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321)},
  author = {Jeff P. Sharman and Talha Munir and Sebastian Grosicki and Lindsey E. Roeker and John M. Burke and Christine I. Chen and Norbert Grzasko and George Follows and Zoltán Mátrai and Alessandro Sanna and Lugui Qiu and Ru Feng and Vu Minh Hua and Wojciech Jurczak and Matthias Ritgen and Shuhua Yi and Francesc Bosch and Catherine C. Coombs and Katherine Bao and Vishalkumar Patel and Bin Liu and Livia Compte and Ananya Guntur and Denise Y. Wang and Marisa Hill and Ching Ching Leow and Paolo Ghia and Paul M. Barr},
  year = {2025},
  journal = {Journal of Clinical Oncology},
  doi = {10.1200/jco-25-00166},
  url = {https://doi.org/10.1200/jco-25-00166}
}

RIS

TY  - JOUR
TI  - Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor–Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321)
AU  - Jeff P. Sharman
AU  - Talha Munir
AU  - Sebastian Grosicki
AU  - Lindsey E. Roeker
AU  - John M. Burke
AU  - Christine I. Chen
AU  - Norbert Grzasko
AU  - George Follows
AU  - Zoltán Mátrai
AU  - Alessandro Sanna
AU  - Lugui Qiu
AU  - Ru Feng
AU  - Vu Minh Hua
AU  - Wojciech Jurczak
AU  - Matthias Ritgen
AU  - Shuhua Yi
AU  - Francesc Bosch
AU  - Catherine C. Coombs
AU  - Katherine Bao
AU  - Vishalkumar Patel
AU  - Bin Liu
AU  - Livia Compte
AU  - Ananya Guntur
AU  - Denise Y. Wang
AU  - Marisa Hill
AU  - Ching Ching Leow
AU  - Paolo Ghia
AU  - Paul M. Barr
PY  - 2025
JO  - Journal of Clinical Oncology
DO  - 10.1200/jco-25-00166
UR  - https://doi.org/10.1200/jco-25-00166
ER  -

APA

Sharman, J. P., Munir, T., Grosicki, S., Roeker, L. E., Burke, J. M., Chen, C. I., Grzasko, N., Follows, G., Mátrai, Z., Sanna, A., Qiu, L., Feng, R., Hua, V. M., Jurczak, W., Ritgen, M., Yi, S., Bosch, F., Coombs, C. C., Bao, K., Patel, V., Liu, B., Compte, L., Guntur, A., Wang, D. Y., Hill, M., Leow, C. C., Ghia, P., & Barr, P. M. (2025). Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor–Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321). Journal of Clinical Oncology. https://doi.org/10.1200/jco-25-00166

Source records

crossref · retrieved 2026-09-27T06:41:49.864Z